Fosun International to Spin Off Subsidiary Fosun Antigen for Separate Hong Kong Listing

Stock News06-26

Fosun International (00656) has announced that the company, along with its subsidiary Shanghai Fosun Pharmaceutical (Group) Co., Ltd., has jointly applied under Practice Note 15 to The Stock Exchange of Hong Kong Limited. The application seeks approval for the proposed spin-off and separate listing of Fosun Pharmaceutical's subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., on the Main Board of the Hong Kong Stock Exchange.

The Hong Kong Stock Exchange has confirmed that Fosun International and Fosun Pharmaceutical can proceed with the proposed spin-off and listing plan.

Fosun International has been informed that on June 26, 2026, Fosun Antigen, through its joint sponsors, submitted a listing application to the Hong Kong Stock Exchange. This application is for the listing of Fosun Antigen's H shares and permission for them to be traded on the Main Board.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181692196?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181692196","market":"hk","top_or_hot":-1,"title":"Fosun International to Spin Off Subsidiary Fosun Antigen for Separate Hong Kong Listing","media":"Stock News","content":"<p><br><br>\n<b>Fosun International</b> (<b>00656</b>) has announced that the company, along with its subsidiary Shanghai Fosun Pharmaceutical (Group) Co., Ltd., has jointly applied under Practice Note 15 to The Stock Exchange of Hong Kong Limited. The application seeks approval for the proposed spin-off and separate listing of Fosun Pharmaceutical's subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., on the Main Board of the Hong Kong Stock Exchange.<br><br>\nThe Hong Kong Stock Exchange has confirmed that Fosun International and Fosun Pharmaceutical can proceed with the proposed spin-off and listing plan.<br><br>\nFosun International has been informed that on June 26, 2026, Fosun Antigen, through its joint sponsors, submitted a listing application to the Hong Kong Stock Exchange. This application is for the listing of Fosun Antigen's H shares and permission for them to be traded on the Main Board.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun International to Spin Off Subsidiary Fosun Antigen for Separate Hong Kong Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun International to Spin Off Subsidiary Fosun Antigen for Separate Hong Kong Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-26 19:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><br><br>\n<b>Fosun International</b> (<b>00656</b>) has announced that the company, along with its subsidiary Shanghai Fosun Pharmaceutical (Group) Co., Ltd., has jointly applied under Practice Note 15 to The Stock Exchange of Hong Kong Limited. The application seeks approval for the proposed spin-off and separate listing of Fosun Pharmaceutical's subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., on the Main Board of the Hong Kong Stock Exchange.<br><br>\nThe Hong Kong Stock Exchange has confirmed that Fosun International and Fosun Pharmaceutical can proceed with the proposed spin-off and listing plan.<br><br>\nFosun International has been informed that on June 26, 2026, Fosun Antigen, through its joint sponsors, submitted a listing application to the Hong Kong Stock Exchange. This application is for the listing of Fosun Antigen's H shares and permission for them to be traded on the Main Board.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1230","symbol_name":"工业集团企业","start_time":0,"source_url":"","article_id":"1181692196","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181692196","pubTimestamp":1782473074,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":" Fosun International (00656) has announced that the company, along with its subsidiary Shanghai Fosun Pharmaceutical (Group) Co., Ltd., has jointly applied under Practice Note 15 to The Stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1230":"工业集团企业","IPOS":"Renaissance International IPO ETF","00656":"复星国际"},"translate_title":"复星国际将分拆子公司复星抗原单独香港上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"00656":1},"content_text":"Fosun International (00656) has announced that the company, along with its subsidiary Shanghai Fosun Pharmaceutical (Group) Co., Ltd., has jointly applied under Practice Note 15 to The Stock Exchange of Hong Kong Limited. The application seeks approval for the proposed spin-off and separate listing of Fosun Pharmaceutical's subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., on the Main Board of the Hong Kong Stock Exchange.\nThe Hong Kong Stock Exchange has confirmed that Fosun International and Fosun Pharmaceutical can proceed with the proposed spin-off and listing plan.\nFosun International has been informed that on June 26, 2026, Fosun Antigen, through its joint sponsors, submitted a listing application to the Hong Kong Stock Exchange. This application is for the listing of Fosun Antigen's H shares and permission for them to be traded on the Main Board.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181692196","isCrawlerRequest":true}